On 169 occasions anticoagulant therapy for thromboembolic disease was stopped electively and patients were followed for I6 subsequent weeks. Patients with overt occlusive arterial disease at more than one site had a significantly increased liability to relapse when compared with patients with symptomatic disease at a single site. In the group of 134 subjects receiving anticoagulant therapy for coronary arterial disease, occurrence of a thromboembolic episode during the course of treatment and the presence of angina of effort in the months before it was discontinued were both associated with a significant increase in liability to relapse. It is suggested that, ideally, anticoagulant therapy should be continued indefinitely in any patient whose pattern of disease thus increases the likelihood of a thromboembolic recurrence.
Recurrence of thromboembolic disease after discontinuing anticoagulant therapy A study offactors affecting incidence Leon Michaels' From the Faculty of Medicine, University of Manitoba, Winnipeg 3, Manitoba, Canada On 169 occasions anticoagulant therapy for thromboembolic disease was stopped electively and patients were followed for I6 subsequent weeks. The records of those who remained well and those who suffered a relapse were compared in an attempt to identify factors that might affect liability to thromboembolic relapse.
During the follow-up period there were 37 thromboembolic recurrences, an incidence of 22 per cent. None occurred among the patients in whomn the original diagnosis of thromboembolic disease was discarded or when a predisposing cause had ceased to be present. There was an inverse relation between liability to relapse and degree of prothrombin time prolongation.
No significant relation could be shown between liability to relapse and any of the following: sex and age; type and severity of the initiating thromboembolic episode; history of earlier thromboembolic disease or relapse after stopping earlier anticoagulant courses; presence of hypertension, hypercholesterolaemia, or diabetes mellitus; type of anticoagulant drug used, duration of therapy, and method of stopping treatment.
Patients with overt occlusive arterial disease at more than one site had a significantly increased liability to relapse when compared with patients with symptomatic disease at a single site. In the group of 134 subjects receiving anticoagulant therapy for coronary arterial disease, occurrence of a thromboembolic episode during the course of treatment and the presence of angina of effort in the months before it was discontinued were both associated with a significant increase in liability to relapse. It is suggested that, ideally, anticoagulant therapy should be continued indefinitely in any patient whose pattern of disease thus increases the likelihood of a thromboembolic recurrence.
The complications of anticoagulant therapy are such that treatment should not be extended beyond established time limits of usefulness. In men who have suffered a myocardial infarction treatment is of proven value for not more than one or two years (Bjerkelund, I957; Medical Research Council Working Party, I959) . Four to six months has been suggested as the optimal time for treating transient attacks of cerebral ischaemia (Fisher, I964) . However, discontinuing treatment is also not without hazard as there is a high risk of thromboembolic disease recurring. This has been reported in patients who had received anticoagulant drugs for myocardial infarction (Nichol et al., I958) , acute coronary insufficiency (Beamish and Storrie, I965) , transient attacks of cerebral ischaemia (Siekert, i96i) , completed stroke (Marshall, I963) , and embolism secondary to rheumatic heart disease (Carter et al., I958; Cosgriff, '953) .
If it were possible to predetermine which patients are particularly liable to suffer a relapse, the risks associated with needless prolongation of anticoagulant therapy and the hazards of terminating treatment could both be reduced. The present study was therefore undertaken in an attempt to identify any factors affecting liability to thromboembolic recurrences when anticoagulant therapy is stopped electively.
Patients and methods
The present investigation was undertaken as an extension of a previous study in which the effects of discontinuing anticoagulant therapy abruptly or gradually were compared (Michaels and Beamish, I967) . It was based on a follow-up of whom such therapy had been stopped electively during the years I964 to I967. All such patients were studied with the exception of those in whom a haemorrhage had occurred during the last three months of treatment. In all, I5O patients were followed. In I32 the effects of stopping a single anticoagulant course, in I7 the effects of stopping two, and in i the effects of stopping three courses were observed. There was therefore a total of I69 follow-up studies (Table i) . Tabulation and analysis of the data were based on the total number of studies. This was not thought to have weighted the results in any way, as a preliminary analysis showed no connexion between occurrence of relapses after terminating earlier courses of treatment and liability to recurrence during the follow-up period under study (see Table 2 ). The effects on the thromboembolic recurrence rate of the following factors were analysed: sex and age; type and severity of the thromboembolic episode for which anticoagulant therapy was given; extent of vascular disease; history of earlier thromboembolic disease and sequelae of stopping earlier courses of anticoagulant drugs; continuation or otherwise of predisposing causes such as post-operative immobilizing in a patient with thrombophlebitis of a leg; presence or absence of hypertension, hypercholesterolaemia, or diabetes mellitus; occurrence of thromboembolic episodes during the course of treatment and presence or absence of symptoms before its termination; type of anticoagulant drug used, duration of therapy, quality of control, and method of stopping treatment.
Initially the patients were allocated randomly to one of two groups. In one, anticoagulant therapy was 'tailed-off' over a six-week period, and in the other it was stopped abruptly. However, all anticoagulant courses were terminated abruptly after earlier analysis had shown that the method of stopping did not affect the recurrence rate significantly (Michaels and Beamish, I967) . Patients were followed during the six-week 'tailoff' period and for I6 weeks after stopping anticoagulant therapy. They were asked to report untoward occurrences immediately. Otherwise they were reassessed four weeks after stopping treatment and at the end of the follow-up period.
Data were coded for card punching and computer analysis. The significance of differences in the recurrence rates observed in the paired subgroups was estimated by the x2 method, Yates' modification being used when any of the numbers being compared was less than I0.
The following definitions were employed.
The relevantanticoagulant course is any course the effects of whose elective termination is part of the present study.
Earlier anticoagulant courses are any whose termination, elective or otherwise, preceded the start of the relevant course by at least one month. Breaks of less than one month were regarded as temporary interruptions in the relevant anticoagulant course.
The initiating episode is the one for which the relevant anticoagulant course was prescribed.
An earlier episode is any thromboembolic incident preceding the initiating episode by at least three months. An occurrence closer in time and similar in character was regarded as part of the initiating episode.
An intercurrent episode is any major thromboembolic occurrence during the relevant anticoagulant course.
The observation period is the six-week 'tail-off' period and the I6 weeks that followed complete stopping of anticoagulant therapy.
The last three blood pressures recorded during the relevant anticoagulant courses were averaged and hypertension defined as a mean systolic blood pressure greater than 170 and a diastolic greater than Ioo mm. Hg. The highest recorded serum cholesterol was used as a basis for comparisons. Diabetes mellitus was diagnosed if, during a stress-free period, the true plasma glucose exceeded Ioo mg./Ioo ml. fasting or I20 mg./Ioo ml. 2 hours after oral administration of 50 g. glucose.
Results
In 33 patients minor symptoms present before stopping anticoagulant therapy continued subsequently, or new symptoms developed which were considered insufficient to warrant resuming treatment. For purposes of comparison these patients were grouped with the subjects who remained symptom free.
There were three major recurrences in the 'tail-off' period and 34 in the following i6 weeks, giving a total of 37 and a recurrence rate of 22 per cent. Seven patients died, one from a stroke and six from cardiac recurrences, either before anticoagulant therapy could be resumed or within a few days of its being restarted. There were 30 patients who survived the recurrence and in whom long-term anticoagulant therapy was resumed.
No relation could be detected between (Table 5 ).
The three recurrences in the 'tail-off' period occurred when the anticoagulant dosage had been reduced to one-third or less of the previous maintenance level. The recurrence rate in the first week after stopping treatment was higher than at other times, but only slightly so, and there was no pattern to the decline during the follow-up period (Fig.) . However, Enger and B0yersen (I965) found that in patients receiving therapy for cerebral infarction, the post-treatment recurrence rate was not, in fact, higher than in untreated controls. The present findings provide little or no support for the concept that rebound hypercoagulability is an important cause of recurrences. The preponderance of relapses during the first week after discontinuing therapy could be attributed equally well to the underlying disease 'catching up' and was in any case very slight. Differences between the site of the initial episode and the site of relapse were exceptional. Over go per cent of patients receiving anticoagulant drugs for coronary arterial disease had relapses involving the coronary circulation. It is not surprising that a few recurrences affected other systems as there is close association between coronary arterial disease and degenerative arterial disease elsewhere in the body (Friedman, Loveland, and Ehrlich, I968). There were no recurrences among the i6 patients in whom preceding vascular disease played little or no part in causation of the initiating episode, 5 in whom the initial diagnosis of thromboembolic disease was discarded, and Thromboembolic recurrence after discontinuing anticoagulant therapy 363 iI in whom a predisposing cause had ceased to be present. In contrast, a significant link between widespread arterial disease and recurrence rate was found. Length of treatment and liability to relapse were not related. Abrupt termination of treatment did not increase the likelihood of relapse and all recurrences were single. The present findings suggest that in the genesis of relapse any transient hypercoagulable state is of much less importance than the state of the vascular tree.
Irrespective of cause, the relapse rate after stopping anticoagulant therapy electively is high, and this has to be considered when deciding whether to stop treatment. To be able to recognize any subgroups with either a high or a low risk of recurrence would be of considerable practical value. Kamath and Thorne (I969) suggested that such categorizing is not possible, but their data were not analysed with respect to the factors that the present study showed to be of significance.
The present findings indicate that anticoagulant therapy can be stopped with impunity if an initial diagnosis of thromboembolism is later abandoned as erroneous, or if a former predisposing cause has ceased to be present for about four months. Neither an earlier thromboembolic episode nor a relapse after ending an earlier anticoagulant course need affect a decision to terminate treatment.
The absence of a demonstrable association between hypertension, hypercholesterolaemia, and diabetes mellitus on the one hand and the recurrence rate on the other may have been due to insufficient numbers in each category, but it is possible, too, that treatment of these conditions ameliorates any effects on the natural history of thromboembolic disease. For practical purposes, the findings suggest that their presence need not affect a decision to discontinue anticoagulant therapy.
A near significant association between intensity of treatment and recurrence rate was found in the present study, highlighting the need for treatment to be intense enough to prolong the prothrombin time consistently to at least twice the control time. On occasion, it is necessary to decide whether to discontinue therapy in a patient who has received anticoagulant drugs for many years. The present findings contrast with those of Kamath and Thorne (I969) , and suggest that, if otherwise indicated, it is reasonable to stop such treatment, as long duration of therapy does not increase the risk of relapse. As shown previously (Michaels and Beamish, I967) , treatment can be stopped abruptly. This has the advantage of simplicity and eliminates the danger of haemorrhage during the 'tail-off' period.
In patients with arterial disease, no relation could be shown between the recurrence rate and the occurrence of myocardial infarction, shock, rhythm disturbance, or heart failure during the initial episode. These factors need not, therefore, influence a decision to stop treatment.
There is no consensus to date about the optimal duration of a course of anticoagulant therapy for patients with acute cerebrovascular insufficiency. The present series includes I4 such patients, all but one with vertebro-basilar insufficiency. Treatment was stopped after an average of I9 months, and there were no episodes of cerebrovascular insufficiency or stroke during the observation period. The three thromboembolic recurrences were coronary in nature and occurred in patients with coexisting angina of effort. The findings now being reported suggest, therefore, that elective stopping of anticoagulant therapy after one to two years is justified in patients with vertebro-basilar insufficiency provided that they have no manifestations of occlusive arterial disease elsewhere.
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